SCHEMBL5546718

SCHEMBL5546718

CC1(CN2C(=O)C(C)(C)c3ccccc32)CO1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.49
▸ ALDH1A1 P00352 5/20 0.47
▸ LMNA P02545 5/20 0.45
▸ MAPT P10636 2/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CYP2D6 P10635 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ THPO P40225 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ GMNN O75496 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540462 0.85 ALDH1A1 (0.44) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL9202873 0.77 GPR55 (0.56) TP53ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL5335221 0.76 TP53 (0.51) TP53ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL13241879 0.76 TP53 (0.55) TP53ALDH1A1LMNAMAPTCYP2D6
SCHEMBL23865489 0.74 TP53 (0.50) TP53ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL3147117 0.73 ELANE (0.69) TP53ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL7014237 0.73 TP53 (0.52) TP53ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL31559833 0.73 TP53 (0.52) TP53ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL30881990 0.73 ELANE (0.69) TP53ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL5538135 0.73 NOTUM (0.46) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 — — EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TP53 4494/4885ALDH1A1 355/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback